585 related articles for article (PubMed ID: 33649166)
1. Targeting a neoantigen derived from a common
Hsiue EH; Wright KM; Douglass J; Hwang MS; Mog BJ; Pearlman AH; Paul S; DiNapoli SR; Konig MF; Wang Q; Schaefer A; Miller MS; Skora AD; Azurmendi PA; Murphy MB; Liu Q; Watson E; Li Y; Pardoll DM; Bettegowda C; Papadopoulos N; Kinzler KW; Vogelstein B; Gabelli SB; Zhou S
Science; 2021 Mar; 371(6533):. PubMed ID: 33649166
[No Abstract] [Full Text] [Related]
2. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
3. Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers.
Malekzadeh P; Pasetto A; Robbins PF; Parkhurst MR; Paria BC; Jia L; Gartner JJ; Hill V; Yu Z; Restifo NP; Sachs A; Tran E; Lo W; Somerville RP; Rosenberg SA; Deniger DC
J Clin Invest; 2019 Mar; 129(3):1109-1114. PubMed ID: 30714987
[No Abstract] [Full Text] [Related]
4. T cell receptors employ diverse strategies to target a p53 cancer neoantigen.
Wu D; Gowathaman R; Pierce BG; Mariuzza RA
J Biol Chem; 2022 Mar; 298(3):101684. PubMed ID: 35124005
[TBL] [Abstract][Full Text] [Related]
5. Targeting p53 as a general tumor antigen.
Theobald M; Biggs J; Dittmer D; Levine AJ; Sherman LA
Proc Natl Acad Sci U S A; 1995 Dec; 92(26):11993-7. PubMed ID: 8618830
[TBL] [Abstract][Full Text] [Related]
6. Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors.
McCormack E; Adams KJ; Hassan NJ; Kotian A; Lissin NM; Sami M; Mujić M; Osdal T; Gjertsen BT; Baker D; Powlesland AS; Aleksic M; Vuidepot A; Morteau O; Sutton DH; June CH; Kalos M; Ashfield R; Jakobsen BK
Cancer Immunol Immunother; 2013 Apr; 62(4):773-85. PubMed ID: 23263452
[TBL] [Abstract][Full Text] [Related]
7. TCR-mimic bispecific antibodies targeting LMP2A show potent activity against EBV malignancies.
Ahmed M; Lopez-Albaitero A; Pankov D; Santich BH; Liu H; Yan S; Xiang J; Wang P; Hasan AN; Selvakumar A; O'Reilly RJ; Liu C; Cheung NV
JCI Insight; 2018 Feb; 3(4):. PubMed ID: 29467338
[TBL] [Abstract][Full Text] [Related]
8. Bispecific antibodies targeting mutant
Douglass J; Hsiue EH; Mog BJ; Hwang MS; DiNapoli SR; Pearlman AH; Miller MS; Wright KM; Azurmendi PA; Wang Q; Paul S; Schaefer A; Skora AD; Molin MD; Konig MF; Liu Q; Watson E; Li Y; Murphy MB; Pardoll DM; Bettegowda C; Papadopoulos N; Gabelli SB; Kinzler KW; Vogelstein B; Zhou S
Sci Immunol; 2021 Mar; 6(57):. PubMed ID: 33649101
[TBL] [Abstract][Full Text] [Related]
9. Structural basis for oligoclonal T cell recognition of a shared p53 cancer neoantigen.
Wu D; Gallagher DT; Gowthaman R; Pierce BG; Mariuzza RA
Nat Commun; 2020 Jun; 11(1):2908. PubMed ID: 32518267
[TBL] [Abstract][Full Text] [Related]
10. Altered HLA-A2-restricted TP53 epitope induces specific CTL cytotoxicity against hepatocellular carcinoma.
Ye C; Lin S; Hong J; Liu F; Guo G; Chen S; Zhou Z; Lin W; Li J; Ye Y
Eur J Immunol; 2023 May; 53(5):e2250054. PubMed ID: 36794567
[TBL] [Abstract][Full Text] [Related]
11. Selective targeting and potent control of tumor growth using an EphA2/CD3-Bispecific single-chain antibody construct.
Hammond SA; Lutterbuese R; Roff S; Lutterbuese P; Schlereth B; Bruckheimer E; Kinch MS; Coats S; Baeuerle PA; Kufer P; Kiener PA
Cancer Res; 2007 Apr; 67(8):3927-35. PubMed ID: 17440108
[TBL] [Abstract][Full Text] [Related]
12. A Novel T-Cell Engaging Bi-specific Antibody Targeting the Leukemia Antigen PR1/HLA-A2.
Herrmann AC; Im JS; Pareek S; Ruiz-Vasquez W; Lu S; Sergeeva A; Mehrens J; He H; Alatrash G; Sukhumalchandra P; St John L; Clise-Dwyer K; Zha D; Molldrem JJ
Front Immunol; 2018; 9():3153. PubMed ID: 30713535
[TBL] [Abstract][Full Text] [Related]
13. Construction and characterization of a bispecific diabody for retargeting T cells to human carcinomas.
Helfrich W; Kroesen BJ; Roovers RC; Westers L; Molema G; Hoogenboom HR; de Leij L
Int J Cancer; 1998 Apr; 76(2):232-9. PubMed ID: 9537586
[TBL] [Abstract][Full Text] [Related]
14. Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer.
Lo W; Parkhurst M; Robbins PF; Tran E; Lu YC; Jia L; Gartner JJ; Pasetto A; Deniger D; Malekzadeh P; Shelton TE; Prickett T; Ray S; Kivitz S; Paria BC; Kriley I; Schrump DS; Rosenberg SA
Cancer Immunol Res; 2019 Apr; 7(4):534-543. PubMed ID: 30709841
[TBL] [Abstract][Full Text] [Related]
15. Specificity of bispecific T cell receptors and antibodies targeting peptide-HLA.
Holland CJ; Crean RM; Pentier JM; de Wet B; Lloyd A; Srikannathasan V; Lissin N; Lloyd KA; Blicher TH; Conroy PJ; Hock M; Pengelly RJ; Spinner TE; Cameron B; Potter EA; Jeyanthan A; Molloy PE; Sami M; Aleksic M; Liddy N; Robinson RA; Harper S; Lepore M; Pudney CR; van der Kamp MW; Rizkallah PJ; Jakobsen BK; Vuidepot A; Cole DK
J Clin Invest; 2020 May; 130(5):2673-2688. PubMed ID: 32310221
[TBL] [Abstract][Full Text] [Related]
16. Development of a CD8 co-receptor independent T-cell receptor specific for tumor-associated antigen MAGE-A4 for next generation T-cell-based immunotherapy.
Davari K; Holland T; Prassmayer L; Longinotti G; Ganley KP; Pechilis LJ; Diaconu I; Nambiar PR; Magee MS; Schendel DJ; Sommermeyer D; Ellinger C
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33771892
[TBL] [Abstract][Full Text] [Related]
17. A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies.
Skokos D; Waite JC; Haber L; Crawford A; Hermann A; Ullman E; Slim R; Godin S; Ajithdoss D; Ye X; Wang B; Wu Q; Ramos I; Pawashe A; Canova L; Vazzana K; Ram P; Herlihy E; Ahmed H; Oswald E; Golubov J; Poon P; Havel L; Chiu D; Lazo M; Provoncha K; Yu K; Kim J; Warsaw JJ; Stokes Oristian N; Siao CJ; Dudgeon D; Huang T; Potocky T; Martin J; MacDonald D; Oyejide A; Rafique A; Poueymirou W; Kirshner JR; Smith E; Olson W; Lin J; Thurston G; Sleeman MA; Murphy AJ; Yancopoulos GD
Sci Transl Med; 2020 Jan; 12(525):. PubMed ID: 31915305
[TBL] [Abstract][Full Text] [Related]
18. Manipulation of Cell-Type Selective Antibody Internalization by a Guide-Effector Bispecific Design.
Lee NK; Su Y; Bidlingmaier S; Liu B
Mol Cancer Ther; 2019 Jun; 18(6):1092-1103. PubMed ID: 30962321
[TBL] [Abstract][Full Text] [Related]
19. A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells.
Bühler P; Wolf P; Gierschner D; Schaber I; Katzenwadel A; Schultze-Seemann W; Wetterauer U; Tacke M; Swamy M; Schamel WW; Elsässer-Beile U
Cancer Immunol Immunother; 2008 Jan; 57(1):43-52. PubMed ID: 17579857
[TBL] [Abstract][Full Text] [Related]
20. Targeting of human breast cancer by a bispecific antibody directed against two tumour-associated antigens: ErbB-2 and carcinoembryonic antigen.
Dorvillius M; Garambois V; Pourquier D; Gutowski M; Rouanet P; Mani JC; Pugnière M; Hynes NE; Pèlegrin A
Tumour Biol; 2002; 23(6):337-47. PubMed ID: 12677091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
